1. Serum Institute Of India To Resume Clinical Trial Of Oxford Covid-19 Vaccine  India Today
  2. Serum Institute to resume India trial of AstraZeneca's COVID-19 vaccine -report  Reuters
  3. Novavax aims for two billion COVID-19 vaccine doses with expanded Serum Institute deal  Yahoo Finance
  4. There Won't Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers  Futurism
  5. Serum Institute to resume India trial of AstraZeneca's COVID-19 vaccine -report  Reuters
  6. View Full coverage on Google News
Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.

Serum Institute gets approval to resume Indian trial of AstraZeneca COVID vaccine: source | Reuters

An expanded arrangement with a local producer should allow for 2 billion doses to be manufactured annually.An expanded arrangement with a local producer should allow for 2 billion doses to be manufactured annually.

Novavax Doubling Coronavirus Vaccine Production Capacity With Expanded India Deal | The Motley Fool

Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.

There Won’t Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers

Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.

There Won't Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers

Chief executive officer at the Serum Institute of India, Adar Poonawalla, told the Financial Times companies don't have capacity to make enough doses for the entire world before 2024.Chief executive officer at the Serum Institute of India, Adar Poonawalla, told the Financial Times companies don't have capacity to make enough doses for the entire world before 2024.

Companies 'will take four YEARS' to manufacture enough coronavirus vaccine for the world | Daily Mail Online

Coronavirus LIVE Updates: India crossed yet another grim milestone of 50 lakh Covid-19 cases with a spike of 90,123 new cases and 1,290 deaths, the highest in 24 hours so far, the Union Health Ministry has said.Coronavirus LIVE Updates: India crossed yet another grim milestone of 50 lakh Covid-19 cases with a spike of 90,123 new cases and 1,290 deaths, the highest in 24 hours so far, the Union Health Ministry has said.

Coronavirus LIVE Updates: World Still at the Beginning of Pandemic, Warns WHO Expert; Trump Says Covid 19 Will Go Away Without Vaccine - News18

If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.

Why India needs to be a model to the world on Covid vaccine delivery

If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.

Why India needs to be a model to the world on Covid vaccine delivery

The DCGI has also asked SII to submit the details of the medication used as per protocol for the management of the adverse events.The DCGI has also asked SII to submit the details of the medication used as per protocol for the management of the adverse events.

DCGI gives nod to Serum Institute to restart phase 2,3 trials for COVID-19 vaccine

As millions across the nation wait for a coronavirus vaccine to be administered, the chief executive of Serum Institute of India, the world’s biggest vaccine producer, suggested that once developed, a COVID-19 vaccine may not fully reach the population until 2024. The date is because [...]As millions across the nation wait for a coronavirus vaccine to be administered, the chief [...]

Coronavirus Vaccine Won't Be Available to Everyone Until 2024, CEO of World's Biggest Producer Says

Novavax, Inc. (NASDAQ: NVAX), which has a Phase 2 study underway of its coronavirus vaccine candidate NVX-CoV2373, is diligently working on partnerships to ...Novavax, Inc. (NASDAQ: NVAX), which has a Phase 2 study underway of its coronavirus vaccine candidate NVX-CoV2373, is diligently working on partnerships to boost its...

Novavax, Inc. (NASDAQ:NVAX) - Novavax Expands Coronavirus Vaccine Capacity To More Than 2B Doses In 2021 | Benzinga

Access to this page has been denied.

If distribution of the eventual Covid-19 vaccine occurs along economic and political lines, all countries will remain at riskIf distribution of the eventual Covid-19 vaccine occurs along economic and political lines, all countries will remain at risk

The perils of vaccine nationalism - The Mail & Guardian

Prime Minister Narendra Modi announced in his Independence Day speech: India has 3 vaccines. Pune-based Serum Institute of India was the first to produce aPrime Minister Narendra Modi announced in his Independence Day speech: India has 3 vaccines. Pune-based Serum Institute of India was the first to produce a

Coronavirus Vaccine: SII Will Start Phase III Trials In Mid-October! Will India Get The COVID-19 Vaccine By December 2020? | Inventiva

The DCGI has asked SII to submit details of medication used in accordance with the protocol for the management of adverse events.Besides, the drug regulating body of the country has told the Serum Institute to take extra care during screening, provide additional information in informed consent, and closely monitor participants for any adverse events during follow-up of the study

Serum Institute gets nod to resume clinical trials of Oxford COVID-19 vaccine in India

The Serum Institute of India (SII) had got the green signal from the DGCI to restart the re-enrollment procedure for COVID-19 vaccine which is being developed by AstraZeneca and Oxford University following the recommendations made by Data Safety Monitoring Board (DSMB) .The Serum Institute of India (SII) had got the green signal from the DGCI to restart the re-enrollment procedure for COVID-19 vaccine which is being developed by AstraZeneca and Oxford University following the recommendations made by Data Safety Monitoring Board (DSMB) .

Serum Institute Of India Gets DCGI's Green Signal To Resume Phase 2-3 Trials For Oxford-AstraZeneca Covid-19 Vaccine

Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, “3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances.”Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, “3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances.”

Serum Institute will start phase-III trials after clearances: ICMR on COVID vaccine | News - Times of India Videos

The DCGI has asked the company certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which has to be "scrupulously" followed by Serum Institute of India (SII).

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine - The Economic Times

The world's biggest vaccine producer, the Serum Institute of India, has warned it will take until at least 2024 to make enough vaccines to go around.The world's biggest vaccine producer, the Serum Institute of India, has warned it will take until at least 2024 to make enough vaccines to go around.

COVID-19 vaccine won't reach everyone until 2024: Serum Institute of India - Business Insider

Maybe the wait is worth it! Click here to see why a viable coronavirus vaccine might not come fast.Maybe the wait is worth it! Click here to see why a viable coronavirus vaccine might not come fast.

Coronavirus Vaccine - No Rest From COVID-19 Until 2024? | IE

Hindustan TimesDirector General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.Hindustan TimesDirector General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon - coronavirus-crisis - videos - Hindustan Times

A day after Union Health minster Harsh Vardhan assured about the development of a vaccine against the novel coronavirus early next year, Serum Vaccine of India chief executive Adar Poonawalla clarifies,"It’s going to take four to five years until everyone gets the vaccine on this planet", as told to the Financial Times.  Get latest Healthcare online at cnbctv18.com A day after Union Health minster Harsh Vardhan assured about the development of a vaccine against the novel coronavirus early next year, Serum Vaccine of India chief executive Adar Poonawalla clarifies,"It’s going to take four to five years until everyone gets the vaccine on this planet",

Serum Institute CEO warns 'COVID vaccine won't be available to all before 2024-end' - cnbctv18.com

The DCGI has also put certain conditions on SII like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study.

Serum Institute Gets DCGI Nod to Resume Clinical Trial of Oxford COVID-19 Vaccine - The Wire Science

As a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’s Covid‑19 vaccine candidate.US-based Novavax's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirusAs a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’s Covid‑19 vaccine candidate.US-based Novavax's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus

Novavax-Serum Institute to produce for 200 crore Covid-19 vaccine doses

India's COVID-19 case tally has crossed the 50-lakh mark with a spike of 90,123 new cases and 1,290 deaths - the highest the country has seen in 24 hours, the Union Health Ministry said. The total number of people who have died because of the disease now stands at 80,776.India's COVID-19 case tally has crossed the 50-lakh mark with a spike of 90,123 new cases and 1,290 deaths - the highest the country has seen in 24 hours, the Union Health Ministry said. The total number of people who have died because of the disease now stands at 80,776.

Coronavirus India Live Updates: Serum Institute Gets Nod To Resume Oxford COVID-19 Vaccine Trial In India

Surgeon Gen. Echoes Trump, Not Fauci, on Virus ProgressAmerica has made it "over the hump" of COVID-19 "because we're near a vaccine," according to U.S. Surgeon General Dr. Jerome Adams on Monday.

Surgeon Gen. Echoes Trump, Not Fauci, on Virus Progress | Newsmax.com

(Bloomberg Opinion) -- The pressures of the pandemic have fallen hardest on developing countries with weak governments. They’re struggling to determine who is being infected and why, and to mitigate the economic impact of lockdowns and social distancing measures.If it can set up an effective cold chain to distribute doses, other nations might also be able to find a way out of the crisis.   

Coronavirus: India Should Take The Lead on Vaccine Delivery

The DCGI had on September 11 directed SII to suspend new recruitment in phase two and three clinical trials after AstraZeneca paused the clinical trials because of ''an unexplained illness'' in a participant in the study.The DCGI had on September 11 directed SII to suspend new recruitment in phase two and three clinical trials after AstraZeneca paused the clinical trials because of ''an unexplained illness'' in a participant in the study.

Coronavirus vaccine update: Serum Institute gets DCGI nod to resume clinical trial of Oxford's COVID-19 vaccine

Many people are relying on a coronavirus vaccine to bring the world back to normal. But with most potential vaccines still in their testing stages, it's hard to know exactly when we can expect that sense of normalcy again. While widespread predictions, including a recent one from Anthony Fauci, MD, have people ready for a vaccine by the end of the year, that excitement may actually be premature. The CEO of the world's largest vaccine manufacturer has recently come out with a troubling prediction: A COVID vaccine won't be available for everyone around the world until 2024."It's going to take four to five years until everyone gets the vaccine on this planet," Adar Poonawalla, CEO of Serum Institute of India, the world's largest vaccine manufacturer, told the Financial Times in a recent interview.According to the Financial Times, the Serum Institute has partnered with five international pharmaceutical firms to develop a COVID vaccine, including United States based company Novavax and British-Swedish company AstraZeneca.The institute has committed to producing one billion doses of the COVID vaccine, half of which has already been pledged to India. Unfortunately, Poonawalla predicts that that will not be enough. If the COVID vaccine is given in two doses, like the measles, he estimates that the world will actually need 15 billion doses of the vaccine. And seeing as no other vaccine producers have yet committed to making as many doses as the Serum Institute, it's not looking good from a global standpoint."I know the world wants to be optimistic on it…[but] I have not heard of anyone coming even close to that [level] right now," Poonawalla said.Other medical experts have given the impression a COVID vaccine will be available much earlier, however. Francis Collins, MD, director of the National Institutes of Health (NIH), said in July that while it was a "stretch goal," having a vaccine distributed by the end of the year is what the U.S. is aiming for. And Fauci recently said that it was a "safe bet" that a vaccine would be approved by November or December. But that, of course, doesn't mean much for the rest of the world.RELATED: For more up-to-date information, sign up for our daily newsletter.The Serum Institute is the largest vaccine manufacturer globally by volume, according to the Financial Times. The company produces 1.5 billion doses of vaccines for use in more than 170 countries every year for various infectious diseases such as polio, measles, and the flu.The institute is set to produce COVID vaccine doses for 68 countries under its contract with AstraZeneca and to 92 countries under its contract with Novavax. And for more COVID developments, check out These Are the 4 Places People Went Before They Got COVID, Study Says.Many people are relying on a coronavirus vaccine to bring the world back to normal. But with most potential vaccines still in their testing stages, it's hard to know exactly when we can expect that sense of normalcy again. While widespread predictions, including a recent one from Anthony Fauci, MD, have people ready for a vaccine by the end of the year, that excitement may actually be premature. The CEO of the world's largest vaccine manufacturer has recently come out with a troubling prediction: A COVID vaccine won't be available for everyone around the world until 2024."It's going to take four to five years until everyone gets the vaccine on this planet," Adar Poonawalla, CEO of Serum Institute of India, the world's largest vaccine manufacturer, told the Financial Times in a recent interview.According to the Financial Times, the Serum Institute has partnered with five international pharmaceutical firms to develop a COVID vaccine, including United States based company Novavax and British-Swedish company AstraZeneca.The institute has committed to producing one billion doses of the COVID vaccine, half of which has already been pledged to India. Unfortunately, Poonawalla predicts that that will not be enough. If the COVID vaccine is given in two doses, like the measles, he estimates that the world will actually need 15 billion doses of the vaccine. And seeing as no other vaccine producers have yet committed to making as many doses as the Serum Institute, it's not looking good from a global standpoint."I know the world wants to be optimistic on it…[but] I have not heard of anyone coming even close to that [level] right now," Poonawalla said.Other medical experts have given the impression a COVID vaccine will be available much earlier, however. Francis Collins, MD, director of the National Institutes of Health (NIH), said in July that while it was a "stretch goal," having a vaccine distributed by the end of the year is what the U.S. is aiming for. And Fauci recently said that it was a "safe bet" that a vaccine would be approved by November or December. But that, of course, doesn't mean much for the rest of the world.RELATED: For more up-to-date information, sign up for our daily newsletter.The Serum Institute is the largest vaccine manufacturer globally by volume, according to the Financial Times. The company produces 1.5 billion doses of vaccines for use in more than 170 countries every year for various infectious diseases such as polio, measles, and the flu.The institute is set to produce COVID vaccine doses for 68 countries under its contract with AstraZeneca and to 92 countries under its contract with Novavax. And for more COVID developments, check out These Are the 4 Places People Went Before They Got COVID, Study Says.

The World's Largest Vaccine Manufacturer Has a Troubling COVID Prediction

At a time when the whole world is eagerly awaiting good news to fight the Coronavirus, Serum Institute of India CEO Adar Poonawalla expressed doubt thatAt a time when the whole world is eagerly awaiting good news to fight the Coronavirus, Serum Institute of India CEO Adar Poonawalla expressed doubt that

Vaccine Might Not Be Available To All Till 2024: Serum Institute CEO - Gulte

Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine - The Serum Institute is working with 5 international companies to develop the coronavirus vaccine.Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine - The Serum Institute is working with 5 international companies to develop the coronavirus vaccine.

Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine

Serum Institute of India chief Adar Poonawalla has said there won't be enough vaccines available for everybody on the planet until 2024 end.  Poonawalla, CEO of the world's largest vaccine maker, said, if vaccination involved two-doses, 15 billion shots will be required to make it available for everybody. "It’s going to take four to five years until everyone gets the vaccineSerum Institute of India chief Adar Poonawalla has said there won't be enough vaccines available for everybody on the planet until 2024 end.  Poonawalla, CEO of the world's largest vaccine maker,

There won't be enough Covid-19 vaccines till 2024, says Serum Institute's Adar Poonawalla | Deccan Herald

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause. Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause. 

Novavax adds antigens to COVID-19 production pact with Indian vaccines giant | FiercePharma

Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.

Widespread Distribution of a COVID-19 Vaccine Could Take As Long as 2024 | BioSpace

The CEO of Serum Institute of India, Adar Poonawalla, speaking to the media has stated that it will take at least four years to make coronavirus vaccines which will be adequate for the entire world.According to Financial Times, he stated that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. Moreover, he added that the world will need 15 billion doses of vaccine if it is taken in two steps.The Serum Institute of India (SII) had earlier initiated human trials for its much talked about ‘Covishield’ vaccine. This vaccine is jointly developed by the University of Oxford and AstraZeneca and is considered to be one of the leading candidates to make the final cut.The first patients for Covishield’s human trials were screened and approved by Pune’s Bharati Vidyapeeth Deemed University Medical College and Hospital. It is said that the hospital aims to have up to 300 to 350 participants for this trial.Positioned to be at the forefront of India’s COVID-19 vaccine push, Serum Institute is the world’s largest vaccine manufacturer by volume, producing doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.The CEO of Serum Institute of India, Adar Poonawalla, speaking to the media has stated that it will take at least four years to make coronavirus vaccines which will be adequate for the entire world.According to Financial Times, he stated that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. Moreover, he added that the world will need 15 billion doses of vaccine if it is taken in two steps.The Serum Institute of India (SII) had earlier initiated human trials for its much talked about ‘Covishield’ vaccine. This vaccine is jointly developed by the University of Oxford and AstraZeneca and is considered to be one of the leading candidates to make the final cut.The first patients for Covishield’s human trials were screened and approved by Pune’s Bharati Vidyapeeth Deemed University Medical College and Hospital. It is said that the hospital aims to have up to 300 to 350 participants for this trial.Positioned to be at the forefront of India’s COVID-19 vaccine push, Serum Institute is the world’s largest vaccine manufacturer by volume, producing doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.

COVID-19 vaccine distribution could take 4 years: Adar Poonawalla | Mumbai

The entire world is racing to develop a coronavirus vaccine but that doesn’t mean everyone across the globe will have access to it anytime soon.The entire world is racing to develop a coronavirus vaccine but that doesn’t mean everyone across the globe will have access to it anytime soon.

Experts warn it might take up to four years to supply COVID-19 vaccine globally

The chief executive of the world's largest vaccine manufacturer says it will take about four or five years to produce enough COVID-19 vaccines to inoculate everyone in the world.

Pharma CEO warns that millions worldwide won't get COVID vaccine until 2024 - SFGate

Read more about Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla on Business Standard. Poonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two stepsPoonawalla estimates that the world will need 15 billion doses of the vaccine if it is taken in two steps

Not enough Covid-19 vaccines for everybody till 2024 end: Adar Poonawalla | Business Standard News

Pharmaceutical companies not increasing capacity quickly enough – Serum Institute chief executive saysPharmaceutical companies not increasing capacity quickly enough – Serum Institute chief executive says

Not enough Covid-19 vaccine for all until 2024, says biggest producer

Serum Institute, which is in Pune, has partnered with five international pharmaceutical companies, including AstraZeneca and Novavax, to develop a vaccine and pledged to manufacture one billion doses, out of which it has promised 50% to India.Serum Institute, which is in Pune, has partnered with five international pharmaceutical companies, including AstraZeneca and Novavax, to develop a vaccine and pledged to manufacture one billion doses, out of which it has promised 50% to India.

Coronavirus Vaccine Won’t Be Available to Everyone Before End of 2024, Says Serum Institute Chief

The chief executive of the world’s largest vaccine producer is cautioning that the world’s population may not be fully vaccinated against the coronavirus until at least the end of 2024, he said in an interview with the Financial Times.The chief executive of the world’s largest vaccine producer is cautioning that the world’s population may not be fully vaccinated against the coronavirus until at least the end of 2024, he said in an interview with the Financial Times.

Vaccine producer says it could take ‘four to five years’ for the world to receive a COVID-19 dose - The Boston Globe

corona vaccine available in india - Covid-19 vaccine, Serum Institute's big announcement on coronavirus vaccine will not be available for everybody in the world to be immunised until the end of 2024.In a big blow to the expectations regarding the covid-19 vaccine, the Serum Institute of India has said adequate coronavirus vaccine will not be available for everybody in the world to be immunised until the end of 2024. The chief executive of the world’s largest manufacturer of vaccines, Adar Poonawalla, has said dampened the hopes of a COVID-19 vaccine by year-end in an interview with the Financial Times. He said that pharma firms were not ramping up production capacity swiftly to be able to innoculate the world population in less duration.

Coronavirus vaccine won’t be available to everyone before 2024 end: India's Serum Institute chief, India News News | wionews.com

NEW DELHI: As the world is grappling with the pandemic and is eagerly waiting for the official announcement of a vaccine for COVID-19, the chief executive of the world’s largest vaccine manufacturing firm Mr. Adar Poonawalla has said that there isn't

Coronavirus Vaccine Won’t Be Available to Everyone Before End of 2024, says Serum Institute Chief – The Shillong Times

Serum Institute of India CEO Adar Poonawalla says it would take at least four to five years to immunise the world against COVID-19, the disease caused by the novel coronavirus.Serum Institute of India CEO Adar Poonawalla says it would take at least four to five years to immunise the world against COVID-19, the disease caused by the novel coronavirus.

Adar Poonawalla, the CEO of the Serum Institute of India (SII), that has taken up the mammoth task of mass-producing coronavirus vaccine, has said the dose will not be available for the entire world before the end of 2024Adar Poonawalla, the CEO of the Serum Institute of India (SII), that has taken up the mammoth task of mass-producing coronavirus vaccine, has said the dose will not be available for the entire world before the end of 2024

Coronavirus vaccine won't be available for all before 2024-end: Poonawalla

Serum Institute, Serum Institute CEO, Adar Poonawalla, Coronavirus vaccine won’t be available to everyone before end of 2024, covid vaccine, coronavirus vaccine update, The chief executive of the world’s largest manufacturer of vaccines, Serum Institute has said that adequate coronavirus vaccine will not be available for everybody in the world to be immunised until the end of 2024.

Coronavirus vaccine won’t be available to everyone before end of 2024: Serum Institute CEO Adar Poonawalla | India News – India TV